To receive your instant certificate, you must "Sign In" or "Sign Up" in the top right corner.
ORIGINAL RELEASE: April 1, 2021
EXPIRATION: April 30, 2022
MAXIMUM CREDITS: 1.5 AMA PRA Category 1 Credits™
CLICK BELOW TO PROCEED TO PROGRAM
ACTIVITY DESCRIPTION AND PURPOSE
The prevalence of age-related macular degeneration (AMD) and diabetic macular edema is increasing and, with it, the number of individuals at risk of vision loss. The standard of care includes frequent injections to regain and maintain vision, but attaining adequate injection frequency and subsequent visual acuity maintenance in the real world using current anti–vascular endothelial growth factor therapies has proven difficult. In response, numerous clinical trials have evaluated drugs with novel mechanisms of action intended to prolong duration of action and reduce injection burden for both neovascular AMD and diabetic macular edema. This educational activity will highlight new data on late diagnosis and undertreatment of neovascular AMD, review the molecular characteristics and clinical efficacy and safety data for new and emerging treatments for retinal vascular diseases, and discuss a clinical case to demonstrate the role these new therapies can play in disease management. The desired results of this educational activity are for retina specialists and other ophthalmologists to translate evidence supporting established, newly approved, and emerging therapies to achieve optimal visual and anatomic outcomes for patients with retinal disease.
This educational activity is intended for retina specialists and other ophthalmologists managing retinal disease.
After completing this activity, participants will be better able to:
- Describe the different mechanisms of extended therapeutic effect for investigational and current treatments for retinal diseases
- Interpret clinical trial data for approved and emerging treatments for retinal diseases
- Develop individualized treatment plans for patients with nAMD that optimize both treatment burden and long-term VA gains
- Integrate treatment strategies into practice that maximize visual acuity gains and minimize treatment burden
MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
MedEdicus LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
INSTRUCTIONS FOR OBTAINING CREDIT
To obtain AMA PRA Category 1 Credit™ for this activity, please read the monograph, consult referenced sources as necessary, and complete the post test and evaluation online. Upon passing with a score of 70% or higher, a certificate will be made available immediately.
MedEdicus requires that anyone who is in a position to control the content of this educational activity disclose all relevant financial relationships with any commercial interest. Financial relationship information is collected and resolved prior to the educational activity.
Sophie J. Bakri, MD, is a consultant for Adverum, Alimera Sciences, Allegro Ophthalmics, LLC, Allergan, Apellis Pharmaceuticals, F. Hoffmann-La Roche Ltd, Genentech, Inc, Kala Pharmaceuticals, Novartis Pharmaceuticals Corporation, and Oxurion.
Nancy M. Holekamp, MD, receives intellectual rights/is a patent holder of Katalyst Surgical; is a consultant for AbbVie Inc, Acucela Inc, Allergan, Apellis Pharmaceuticals, Clearside Biomedical, Inc, Gemini Therapeutics, Genentech, Inc, Gyroscope, Ionic Biomedical, Inc, Katalyst Healthcares & Life Sciences, Nacuity Pharmaceuticals, Inc, Notal Vision, Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals, Inc; is on the speakers bureau for Allergan, Genentech, Inc, Regeneron Pharmaceuticals, Inc, and Spark Therapeutics, Inc; is a contracted researcher for Gemini Therapeutics, Genentech, Inc, Gyroscope, Notal Vision, and Regeneron Pharmaceuticals, Inc; and has ownership interest in Katalyst Healthcares & Life Sciences.
Peter K. Kaiser, MD, is a consultant for Aerie Pharmaceuticals, Inc, Alcon, Allegro Ophthalmics, LLC, Allergan, Alzheon, Inc, Annexon Inc, AsclepiX, Bausch & Lomb Incorporated, Bayer Corporation, bioeq GmbH, Biogen Idec, Bionic Vision Technologies, Boehringer Ingelheim International GmbH, Carl Zeiss Meditec, Inc, Chengdu Kanghong Pharmaceutical Group Co Ltd, Clearside Biomedical, Inc, DTx Pharma, Duet Therapeutics, Eyevensys, Formycon AG, Galecto Biotech, Galimedix Therapeutics, Inc, Gemini Therapeutics, Glaukos Corporation, Innovent Biologics, Inc, iRenix, IVERIC bio, jCyte, Kala Pharmaceuticals, Kanaph Therapeutics, Kodiak Sciences Inc, NGM Biopharmaceuticals, Novartis Pharmaceuticals Corporation, Ocugenix, Oculis, Ocuphire Pharma, OcuTerra Therapeutics Inc, Omeros Corporation, Opthea, Oxurion NV, Palatin Technologies, Inc, Regeneron Pharmaceuticals, Inc, Regenxbio Inc, Retinal Sciences, Retrotope Inc, Roivant Sciences Ltd, Sandoz International GmbH, Santen Inc, Spark Therapeutics, Inc, Stealth BioTherapeutics Inc, Sustained Nano Systems, LLC, Takeda Pharmaceuticals USA, Inc, and Thea Pharmaceuticals Limited; is on the speakers bureau for Novartis Pharmaceuticals Corporation; and has ownership interest in Allegro and IVERIC bio.
Arshad M. Khanani, MD, MA, is a consultant for Adverum, Allergan, Bausch & Lomb Incorporated, Chengdu Kanghong Pharmaceutical Group Co Ltd, EyePoint Pharmaceuticals, Gemini Therapeutics, Genentech, Inc, GrayBug, Inc, Gyroscope, Novartis Pharmaceuticals Corporation, Opthea, Oxurion NV, PolyPhotonix, Recens Medical, Inc, and Regenxbio Inc; is on the speakers bureau for Allergan, Genentech, Inc, and Novartis Pharmaceuticals Corporation; and is a contracted researcher for Adverum, Allergan, Chengdu Kanghong Pharmaceutical Group Co Ltd, Gemini Therapeutics, Genentech, Inc, GrayBug, Inc, Gyroscope, Novartis Pharmaceuticals Corporation, Opthea, Oxurion NV, PolyPhotonix, Recens Medical, Inc, and Regenxbio Inc.
This activity was peer reviewed. The peer reviewer has no relevant financial relationships.
Planners and Managers
MedEdicus planners and managers have no relevant commercial relationships to disclose.
DISCLOSURE OF COMMERCIAL SUPPORT
This continuing medical education activity is supported through an educational grant from Allergan.
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
PROVIDER CONTACT INFORMATION
For questions about this educational activity, please contact MedEdicus LLC at email@example.com.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC, Allergan, or Retina.
This CME activity is copyrighted to MedEdicus LLC ©2021. All rights reserved. 229 CLICK HERE TO PROCEED TO PROGRAM